This enduring educational program is designed to assist healthcare providers who care for adult patients with moderate-to-severe asthma in reducing exacerbations and hospitalizations and improving patient treatment adherence and quality of life. This program will help learners to better align treatment regimens with evidence-based asthma management guidelines, summarize evidence-based best practices to optimize patient education, and employ current clinical evidence on the use of biologic agents in patients with moderate-to-severe asthma.

RELEASED DATE: October 29, 2024
EXPIRATION DATE: October 29, 2025

This program has been developed to educate practitioners who care for patients with chronic obstructive pulmonary disease (COPD) on the emerging role of pro-inflammatory cytokines in COPD progression and treatment, improve their understanding of the evolving clinician trial landscape, and impart strategies to improve patient education and communication. The program provides a unique opportunity to hear the patient’s perspective on their disease journey, and from the treating physician on the clinical strategy that was implemented to manage disease symptoms.

RELEASED DATE: October 30, 2024
EXPIRATION DATE: October 30, 2025

This enduring activity is designed to provide healthcare professionals with a comprehensive understanding of the role of type 2 inflammation in the pathophysiology of Chronic Obstructive Pulmonary Disease (COPD) and its implications for treatment strategies. The latest developments in the treatment of COPD using approved and investigational biologics will be discussed featuring evidence-based and real-world experiences. Participants will gain valuable insights into improving the management of COPD using a multidisciplinary approach.

RELEASED DATE: May 17, 2025
EXPIRATION DATE: May 17, 2026

This enduring program consists of presentations from expert faculty and simulation challenge animations that will explain immune dysfunction and the pathogenesis of moderate-to-severe asthma, currently available and emerging targeted therapies used for asthma, and the usefulness and application of guidelines and biomarkers to guide treatment selection for this disease.

This enduring activity is designed to provide healthcare professionals with the latest evidence and strategies for managing moderate-to-severe asthma, focusing on biologic therapies. The program will review all the available tools required to make informed decisions about choosing the right biologic treatment options along with providing patient-centered communication and education to improve the overall management of patients suffering with this restrictive lung condition.

RELEASED DATE: May 17, 2025
EXPIRATION DATE: May 17, 2026

This enduring Grand Rounds program is focused on chronic obstructive pulmonary disease (COPD). It will provide you with an update on new information regarding the complex pathogenesis and pathophysiology of COPD, enhance your understanding of biologics targeting mediators of type 2 inflammation for treating COPD in appropriate patient populations, and improve your ability to provide timely referrals to COPD specialists and participate in multidisciplinary management teams (MDTs). This interactive program combines didactic instruction with case-based discussions.

RELEASED DATE: January 31, 2025
EXPIRATION DATE: January 31, 2026

This educational enduring program will assist healthcare providers who care for adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) with type 2 inflammation in reducing exacerbations and preventing hospitalizations and emergency care visits. This program will help learners to better align treatment regimens with evidence-based COPD management guidelines, identify potential therapeutic targets, and summarize evidence-based best practices to optimize specialty and multidisciplinary care referral. Last, this program provides learners with current clinical evidence on the use of biologic agents in patients with moderate-to-severe COPD.

RELEASED DATE: October 29, 2024
EXPIRATION DATE: October 29, 2025